Results 61 to 70 of about 6,178 (191)

Contemporary Management of Thalassemia: A Perspective on Current Standards and the Emergence of FDA‐Approved Oral Therapy

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Thalassemia is an inherited hemoglobin disorder characterized by ineffective erythropoiesis, chronic anemia, and progressive multisystem complications that require lifelong management. Current treatment relies on regular red blood cell transfusions, iron chelation therapy, and supportive multidisciplinary care, while ...
Fnu Zainab, Abdul Haseeb Hasan, Muhammad Hafi Abid, Muhammad Ali Abid   +3 more
wiley   +1 more source

The potential of deferasirox as a novel therapeutic modality in gastric cancer [PDF]

, 2016
Background: Iron is a crucial element for cell proliferation, growth, and metabolism. However, excess iron and altered iron metabolism are both associated with tumor initiation and tumor growth. Deferasirox is an oral iron chelator. Although some studies
���������
core   +1 more source

Ferroptosis: Newly Emerged Regulator for Human Disease

MedComm, Volume 7, Issue 9, September 2026.
Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao, Lin Ye, Tianqi Jiang, Mengyuan Liu, Yuxia Zhou   +4 more
wiley   +1 more source

Leg Ulcers in Thalassaemia: A Comparative Retrospective Review of Transfusion‐Dependent and Non‐Transfusion‐Dependent Patients

International Wound Journal, Volume 23, Issue 9, September 2026.
ABSTRACT To compare clinical and laboratory characteristics of transfusion‐dependent and non‐transfusion‐dependent beta thalassaemia patients with leg ulcers, and to identify contributing and protective factors We retrospectively reviewed 12 patients with beta thalassaemia and leg ulcers (seven transfusion‐dependent and five non‐transfusion‐dependent ...
Sacha El Khoury, Nicole Charbel, Farouk Kabbara, Joseph Klim, Ghida Ismail, Farah Ismail, Suzanne Koussa, Ali Taher   +7 more
wiley   +1 more source

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +1 more source

Investigating the Effect of Iron Chelation Therapy With Deferasirox on Liver Aminotransferases Levels in Transfusion-dependent β-thalassemia Patients [PDF]

مجله دانشگاه علوم پزشکی گیلان
Background Various body tissues of β-thalassemia patients are exposed to the destructive effects of iron overload due to chronic blood transfusions. Therefore, the decision to start regular blood transfusion therapy for these patients often leads to the ...
Shayan Pourkazem, Mohammadreza Sharifi Rad, Adel Baghersalimi, Soodeh Salehi, Mercedeh Enshaei, Vahid Aminzadeh, Behrang Motamed, Bahram Darbandi   +7 more
doaj  

Chelation of aluminum by combining deferasirox and deferiprone in rats

, 2011
The hypothesis that two known chelators deferasirox and deferiprone (L1) might be more efficient as combined treatment than as single therapies in removing aluminum from the body was tested in a new acute rat model.
Amir Shokooh Saljooghi
core   +1 more source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

American Journal of Hematology, Volume 101, Issue 8, Page 1969-1979, August 2026.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth, Selim Corbacioglu, Josu de la Fuente, Mattia Algeri, Joachim Rupprecht, Kevin H. M. Kuo, Ami J. Shah, Peter Lang, Hayley Merkeley, Ben Carpenter, Markus Y. Mapara, Robert I. Liem, Stephan Grupp, Yogi Chopra, Amanda M. Li, Janet L. Kwiatkowski, Melanie Kirby‐Allen, Maria Domenica Cappellini, Antonis Kattamis, Sakellarios Zairis, Tina Liu, William Hobbs, Haydar Frangoul, Franco Locatelli, Roland Meisel, on behalf of the CLIMB THAL‐111 and CLIMB‐131 Study Groups   +25 more
wiley   +1 more source

Co(III)-deferasirox komplexek szintézise és vizsgálata

, 2017
A deferasirox és dekarboxi-deferasiorx Co(III)-komplexeit állítottam elő, melyek tisztaságáról és összetételéről különböző vizsgálatokkal győződtünk meg.
Nyujtó, Nikolett
core  

H Syndrome Associated With Pure Red Cell Aplasia, Rosai–Dorfman Disease, and Sensorineural Hearing Loss: Phenotypic Variability in Three Children With the Same SLC29A3 Mutation

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT H syndrome is a rare autosomal recessive disorder caused by mutations in the SLC29A3 gene. We report three pediatric patients with a homozygous c.1309G>A (p.Gly437Arg) mutation presenting with distinct phenotypic variations. These cases expand the clinical spectrum and emphasize the importance of early genetic diagnosis and family counseling.
Mohammad Najajrah, Hadeel I. Bouzia, Nermin K. Darawi, Fatima S. Hajjaj, Nour H. Moosa, Noor M. Awad   +5 more
wiley   +1 more source